[Celecoxib inhibits gastric adenocarcinoma growth via inducing expression of human nonsteroidal anti-inflammatory drug activated gene].
OBJECTIVE
To investigate the effect of cyclooxygenase2 inhibitor celecoxib on the suppression of human gastric cancer (GC) growth and the induction of nonsteroidal anti-inflammatory drug activated gene (NAG-1) expression.


METHODS
Thirty-six GC patients were randomly divided into two groups before curative surgery. Celecoxib group patients (n = 20) took celecoxib orally 0.2 g, qd for 7 days before operation. Control group (n = 16) took no medication before resection. The resected specimens were used for histological and pathological study, and apoptosis of tumor cells were evaluated by the terminal deoxynucleotide transferase (TdT)-mediated dUTP nick end-labeling assay (TUNEL). COX-2 expression was assessed by immunohistochemical staining. Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) assay was used to measure NAG-1 mRNA expression in GC tissue of both groups.


RESULTS
Apoptosis IOD score of the GC cells in celecoxib group was significantly higher than that in control group (180.2 +/- 42.67 vs 10.28 +/- 5.02, P < 0.05). NAG-1 mRNA expression was higher in celecoxib group (0.22 +/- 0.13) than in the control (0.12 +/- 0.08, P < 0.05). There was no significant difference of COX-2 expression rate between both groups (75.0% vs 87.6%, P > 0.05).


CONCLUSIONS
Celecoxib can enhance apoptosis of GC cell by induction of NAG-1 gene transcription in human.
Wang
Rui
R
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, China.
Ciren
Yang-Jin
YJ
Yang
Jin-Lin
JL
Zhang
Bo
B
Chen
Jia-Ping
JP
Tang
Cheng-Wei
CW
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D000328:Adult; D000368:Aged; D017209:Apoptosis / Q000187:drug effects; D000068579:Celecoxib; D049109:Cell Proliferation / Q000187:drug effects; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D005260:Female; D055436:Growth Differentiation Factor 15 / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D013449:Sulfonamides / Q000627:therapeutic use*
D052246:Cyclooxygenase 2 Inhibitors; C526140:GDF15 protein, human; D055436:Growth Differentiation Factor 15; D011720:Pyrazoles; D012333:RNA, Messenger; D013449:Sulfonamides; D000068579:Celecoxib